MY129431A - Prodrugs to d-prolines - Google Patents
Prodrugs to d-prolinesInfo
- Publication number
- MY129431A MY129431A MYPI20024679A MYPI20024679A MY129431A MY 129431 A MY129431 A MY 129431A MY PI20024679 A MYPI20024679 A MY PI20024679A MY PI20024679 A MYPI20024679 A MY PI20024679A MY 129431 A MY129431 A MY 129431A
- Authority
- MY
- Malaysia
- Prior art keywords
- compounds
- hydroxy
- treatment
- lower alkyl
- signify
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
THE INVENTION RELATES TO COMPOUNDS OF FORMULAE WHEREIN R1 AND R2 ARE INDEPENDENTLY FROM EACH OTHER AND SIGNIFY LOWER ALKOXY, LOWER ALKENYLOXY, BENZYLOXY, HYDROXY, -OCH(CH3)OC(O)-LOWER ALKYL OR -OCH2C(O)N(R3)(R4), WITH THE PROVISO THAT ONLY ONE OF R1 OR R2 MAY BE HYDROXY;R3 AND R4 ARE INDEPENDENTLY FORM EACH OTHER AND SIGNIFY HYDROGEN, LOWER ALKYL, LOWER ALKENYL OR CYCLOALKYL; OR R1 AND R2 FROM TOGETHER WITH THE CARBON ATOM , TO WHICH THEY ARE ATTACHED THE LINKING GROUP X, WHEREIN X IS -O(CH2)NCH=CH(CH2)NO-OR-O(CH2)MO-;N IS 1,2 OR 3; AND M IS 4-8.AS WELL AS PHARMACEUTICALLY ACCEPTABLE SALTS OF SAID COMPOUNDS. COMPOUNDS OF THE PRESENT INVENTION CAN BE USED FOR THE TREATMENT OF DISEASES WHERE SERUM AMYLOID P COMPONENT DEPLETION HAS A BENEFICIAL EFFECT, IN PARTICULAR IN THE TREATMENT OR PREVENTION OF ALL FORMS OF CENTRAL AND SYSTEMATIC AMYLOIDOSIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01129793 | 2001-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY129431A true MY129431A (en) | 2007-03-30 |
Family
ID=8179542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20024679A MY129431A (en) | 2001-12-14 | 2002-12-13 | Prodrugs to d-prolines |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6903129B2 (en) |
| EP (2) | EP1458680A1 (en) |
| JP (1) | JP4192100B2 (en) |
| KR (1) | KR100678785B1 (en) |
| CN (1) | CN100368397C (en) |
| AR (1) | AR038010A1 (en) |
| AU (1) | AU2002361982B2 (en) |
| BR (1) | BR0214932A (en) |
| CA (1) | CA2470037C (en) |
| GT (1) | GT200200275A (en) |
| HK (1) | HK1076100A1 (en) |
| HR (1) | HRP20040494A2 (en) |
| HU (1) | HUP0402600A3 (en) |
| IL (2) | IL162158A0 (en) |
| MX (1) | MXPA04005693A (en) |
| MY (1) | MY129431A (en) |
| NO (1) | NO20042979L (en) |
| NZ (1) | NZ533188A (en) |
| PA (1) | PA8561201A1 (en) |
| PE (1) | PE20030764A1 (en) |
| PL (1) | PL370803A1 (en) |
| RU (1) | RU2305679C2 (en) |
| TW (1) | TWI225400B (en) |
| UY (1) | UY27584A1 (en) |
| WO (1) | WO2003051836A1 (en) |
| ZA (1) | ZA200404546B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| UA108227C2 (en) | 2010-03-03 | 2015-04-10 | ANTIGENCY PROTEIN | |
| RU2530601C2 (en) * | 2012-10-05 | 2014-10-10 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Zinc-dependent beta-amyloid dimer formation inhibitor |
| GB201407506D0 (en) * | 2014-04-29 | 2014-06-11 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| WO2017072090A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| SI0915088T1 (en) | 1997-10-31 | 2002-12-31 | F. Hoffmann-La Roche Ag | D-proline derivatives |
-
2002
- 2002-12-02 US US10/307,699 patent/US6903129B2/en not_active Expired - Lifetime
- 2002-12-06 BR BR0214932-0A patent/BR0214932A/en not_active Application Discontinuation
- 2002-12-06 JP JP2003552723A patent/JP4192100B2/en not_active Expired - Fee Related
- 2002-12-06 WO PCT/EP2002/013827 patent/WO2003051836A1/en not_active Application Discontinuation
- 2002-12-06 CN CNB028249348A patent/CN100368397C/en not_active Expired - Fee Related
- 2002-12-06 HU HU0402600A patent/HUP0402600A3/en unknown
- 2002-12-06 RU RU2004121783/04A patent/RU2305679C2/en not_active IP Right Cessation
- 2002-12-06 EP EP02796578A patent/EP1458680A1/en not_active Withdrawn
- 2002-12-06 PL PL02370803A patent/PL370803A1/en not_active Application Discontinuation
- 2002-12-06 NZ NZ533188A patent/NZ533188A/en not_active IP Right Cessation
- 2002-12-06 MX MXPA04005693A patent/MXPA04005693A/en active IP Right Grant
- 2002-12-06 KR KR1020047009036A patent/KR100678785B1/en not_active IP Right Cessation
- 2002-12-06 EP EP06020711A patent/EP1743884A1/en not_active Withdrawn
- 2002-12-06 IL IL16215802A patent/IL162158A0/en unknown
- 2002-12-06 CA CA2470037A patent/CA2470037C/en not_active Expired - Fee Related
- 2002-12-06 AU AU2002361982A patent/AU2002361982B2/en not_active Ceased
- 2002-12-10 PE PE2002001184A patent/PE20030764A1/en not_active Application Discontinuation
- 2002-12-11 TW TW091135829A patent/TWI225400B/en not_active IP Right Cessation
- 2002-12-11 PA PA20028561201A patent/PA8561201A1/en unknown
- 2002-12-12 AR ARP020104818A patent/AR038010A1/en unknown
- 2002-12-13 MY MYPI20024679A patent/MY129431A/en unknown
- 2002-12-13 GT GT200200275A patent/GT200200275A/en unknown
- 2002-12-13 UY UY27584A patent/UY27584A1/en not_active Application Discontinuation
-
2004
- 2004-05-24 IL IL162158A patent/IL162158A/en not_active IP Right Cessation
- 2004-06-01 HR HR20040494A patent/HRP20040494A2/en not_active Application Discontinuation
- 2004-06-08 ZA ZA200404546A patent/ZA200404546B/en unknown
- 2004-07-13 NO NO20042979A patent/NO20042979L/en not_active Application Discontinuation
-
2005
- 2005-09-16 HK HK05108123A patent/HK1076100A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05006420A (en) | Pyrimidine derivates for the treatment of abnormal cell growth. | |
| NL350075I2 (en) | ||
| DK1446128T3 (en) | Use of estrogen compounds in combination with progestogen compounds in hormone replacement therapy | |
| RS20050180A (en) | Novel benzoimidazole derivatives useful as antiproliferative agensts | |
| YU95102A (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| MY139243A (en) | Prodrugs of piperazine and substituted piperidine antiviral agents. | |
| MX2007004183A (en) | Benzoimidazole derivatives useful as antiproliferative agents. | |
| MX2010002820A (en) | Thiazolidinedione analogues for the treatment of hypertension. | |
| TW200744659A (en) | Preparation for preventing and ameliorating wrinkle | |
| SG166791A1 (en) | Novel macrocyclic inhibitors of hepatitis c virus replication | |
| IL172189A (en) | Triheterocyclic compounds, compositions, methods for making and uses thereof | |
| MY135841A (en) | Novel benzodioxoles | |
| TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
| TWI265928B (en) | A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw | |
| SG158869A1 (en) | A tetracycline metal complex in a solid dosage form | |
| NO20062255L (en) | 4-Anilino-3-quinoline carbonitriles for the treatment of chronic myelogenous leukemia (CML) | |
| MY129431A (en) | Prodrugs to d-prolines | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| TW200720265A (en) | Agent for treatment of hematopoietic tumor | |
| GB9824207D0 (en) | Neurological disorders | |
| TW200420292A (en) | Benzofuran derivative | |
| TW200505446A (en) | Inhibitor of cox | |
| RS44004A (en) | Processes for the preparation of substituted bicyclid derivatives for the treatment of abnormal cell growth | |
| AR043271A1 (en) | DIHYDROPIRONAS COMPOUNDS WITH UNITED HETEROCICLES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS THAT HAVE HIV PROTEASA INHIBITING ACTIVITY | |
| MY136065A (en) | Prodrugs to nmda receptor ligands |